Actinic Keratosis Clinical Trial
Official title:
Comparative Intraindividual Study, About the Efficacy and Safety of Treatment of Actinic Keratoses With Photodynamic Therapy Between Acid Methyl Aminolevulinate Cream and Aminolevulinic Gel
Photodynamic therapy technique (PDT) is a conventional technique which is performed applying
the product under occlusion lesions, let it incubate for 3 hours and then exposed skin to a
light source, usually red.
The conclusions of efficacy, tolerance and satisfaction that today are known about PDT with
MAL, but not with ALA, which is a new photosensitizer indicated for Actinic Keratoses. The
pharmaceutical form of ALA is a gel, which gives a hypothetical better penetration and
consequently it is more effectively.
Intraindividual comparative study, to evaluate efficacy and safety of the treatment of
actinic keratosis with photodynamic therapy between methyl aminolevulinate cream (MAL) and
aminolevulinic acid nanosoma gel (ALA).
MAL cream: is an antineoplastic agent used as a photosensitizer for photodynamic therapy
(PDT). The mode of action of methyl aminolevulinate in PDT was shown in the pharmacodynamic
(PD) studies. In the target cells,methyl aminolevulinate was converted to photoactive
porphyrins, including protoporphyrinIX (PpIX), which are the active photosensitizers. Upon
light activation, the photosensitizers give rise to the production of cytotoxic singlet
oxygen species which destroy the target cells.
ALA gel: Following topical application of 5-aminolaevulinic acid, the substance is
metabolized to protoporphyrin IX, a photoactive compound which accumulates intracellularly
in the treated actinic keratosis lesions. Protoporphyrin IX is activated by illumination
with red light of a suitable wavelength and energy. In the presence of oxygen, reactive
oxygen species are formed. The latter causes damage of cellular components and eventually
destroys the target cells.
Photodynamic therapy technique (PDT) is a conventional technique which is performed applying
the product under occlusion lesions, let it incubate for 3 hours and then exposed skin to a
light source, usually red.
The conclusions of efficacy, tolerance and satisfaction that today are known about PDT with
MAL, but not with ALA, which is a new photosensitizer indicated for QA. The pharmaceutical
form of ALA is a gel, which gives a hypothetical better penetration and consequently it is
more effectively.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03013647 -
Daylight Photodynamic Therapy for Actinic Keratosis and Skin Field Cancerization
|
N/A | |
| Completed |
NCT02674048 -
Metvix Daylight PDT in Actinic Keratosis
|
||
| Completed |
NCT02421471 -
PMS to Evaluate the Safety and Efficacy of Picato® Gel
|
||
| Completed |
NCT02239679 -
Controlled Study of the Occurrence of Actinic Keratosis on the Face After Cryotherapy + Aminolevulinic Acid (ALA) Photodynamic Therapy
|
Phase 2 | |
| Completed |
NCT01686152 -
Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
|
Phase 3 | |
| Completed |
NCT01449513 -
PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Reflectance Confocal Microscopy
|
Phase 1 | |
| Terminated |
NCT01525329 -
Combination Therapy With 5-Fluorouracil and Photodynamic Therapy in Post-transplant Premalignant Skin Disease
|
Phase 3 | |
| Completed |
NCT01444989 -
Development and Validation of a Quality of Life Instrument for Actinic Keratosis
|
N/A | |
| Terminated |
NCT01203878 -
Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy
|
Phase 4 | |
| Completed |
NCT00989313 -
A Long Term Follow up Study of Patients Who Have Complete Clearance of Their Actinic Keratosis (AK) Lesions at the Day 57 Visit in the PEP005-028 Study
|
Phase 3 | |
| Completed |
NCT00306800 -
Metvix PDT Versus Vehicle PDT With Aktilite CL128 Lamp in Patients With Actinic Keratosis on the Face and Scalp
|
Phase 3 | |
| Completed |
NCT00375739 -
Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses
|
Phase 2 | |
| Completed |
NCT03285490 -
A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on Actinic Keratosis on Face or Scalp (AK004)
|
Phase 3 | |
| Completed |
NCT03319251 -
Biomarker Database Registry for Photodynamic Therapy
|
||
| Completed |
NCT02866695 -
Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of AK on the Face in Solid Organ Transplant Recipients
|
Phase 4 | |
| Completed |
NCT02952898 -
Study Comparing GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses
|
Phase 3 | |
| Completed |
NCT02984072 -
Menthol for PDT Pain Relief
|
Phase 4 | |
| Recruiting |
NCT03684772 -
Topical Ionic Contra-Viral Therapy in Actinic Keratosis
|
Phase 2 | |
| Completed |
NCT02878382 -
Potential Impact of Patient Vitamin D Status in AK Response to MAL-PDT
|
N/A | |
| Completed |
NCT02938715 -
Pilot Study of the Pragmatic Use of Mobile Phone Based Follow up of Actinic Keratoses Treated With Topical 5-fluorouracil
|
N/A |